ERBB2 and breast carcinoma: When hormone receptor-positive HER2 positive patients (luminal B/HER2 positive patients) were added to ER+ and/or PR+, HER2− patients, a total of 83.6% of our patients had hormone receptor-positive breast carcinoma.